etoposide phosphate (Etopophos)

02/01/1997 - "Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer."
12/01/1996 - "A pharmacodynamic evaluation of hematologic toxicity observed with etoposide phosphate in the treatment of cancer patients."
01/01/1996 - "Pharmacokinetic evaluation of high-dose etoposide phosphate after a 2-hour infusion in patients with solid tumors."
01/01/1995 - "Thirty-nine patients with documented cancers received a total of 75 cycles of etoposide phosphate. "
01/01/1997 - "Eleven patients with advanced cancer refractory to standard therapy were treated with etoposide phosphate given over 1-2 hours on three consecutive days. "

11/01/1998 - "A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer."
06/01/1995 - "The combination of etoposide phosphate and cisplatin is effective in the treatment of small-cell lung cancer, and can be administered with acceptable toxicity. "
06/01/1995 - "The combination of etoposide phosphate and cisplatin is effective in the treatment of small cell lung cancer, and can be administered with acceptable toxicity. "
07/01/2001 - "Etoposide phosphate with carboplatin in the treatment of elderly patients with small-cell lung cancer: a phase II study."
06/01/1995 - "This randomized phase II study evaluated the efficacy and toxicity of etoposide phosphate when used in combination with cisplatin in the treatment of small-cell lung cancer. "

01/01/2017 - "The objectives of this study were to assess the safety, the tolerability and the efficacy of intravenous etoposide phosphate in dogs with multicentric lymphoma. "
01/01/2017 - "Dose escalation study to evaluate safety, tolerability and efficacy of intravenous etoposide phosphate administration in 27 dogs with multicentric lymphoma."
01/01/2017 - "Twenty-seven owned-dogs with high-grade multicentric lymphoma were enrolled and treated with three cycles of etoposide phosphate IV injections every 2 weeks. "
02/18/2020 - "Conclusion: F14512 showed strong therapeutic efficacy against spontaneous NHL and exhibited a clinical benefice in Pgp-overexpressing lymphoma superior to etoposide phosphate. "
08/01/2001 - "Bioequivalence investigation of high-dose etoposide and etoposide phosphate in lymphoma patients."

01/01/2023 - "Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index."
10/01/1995 - "Etoposide phosphate (EP) is a water-soluble derivative of etoposide (VP-16), a semisynthetic podophyllotoxin which is useful in the treatment of a wide variety of hematological malignancies and solid tumors. "

06/01/2022 - "Immediate severe hypersensitivity reaction to etoposide phosphate: Case report and review of the literature."
09/01/2020 - "We report a case of severe hypersensitivity reaction to etoposide phosphate in an old man. "
09/01/2020 - "Hypersensitivity to etoposide phosphate has rarely been documented. "
09/01/2020 - "Severe hypersensitivity reaction to etoposide phosphate: A case report."
03/01/2020 - "Etoposide phosphate rate was not associated with hypersensitivity. "